178 related articles for article (PubMed ID: 33966346)
1. Delineating binding potential, stability of Sulforaphane-N-acetyl-cysteine in the active site of histone deacetylase 2 and testing its cytotoxicity against distinct cancer lines through stringent molecular dynamics, DFT and cell-based assays.
Ganai SA; Srinivasan P; Rajamanikandan S; Shah BA; Mohan S; Gani M; Padder BA; Qadri RA; Bhat MA; Baba ZA; Yatoo MA
Chem Biol Drug Des; 2021 Sep; 98(3):363-376. PubMed ID: 33966346
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and evaluation of novel N-hydroxybenzamides/N-hydroxypropenamides incorporating quinazolin-4(3H)-ones as histone deacetylase inhibitors and antitumor agents.
Hieu DT; Anh DT; Tuan NM; Hai PT; Huong LT; Kim J; Kang JS; Vu TK; Dung PTP; Han SB; Nam NH; Hoa ND
Bioorg Chem; 2018 Feb; 76():258-267. PubMed ID: 29223029
[TBL] [Abstract][Full Text] [Related]
3. Rational design of selective HDAC2 inhibitors for liver cancer treatment: computational insights into the selectivity mechanism through molecular dynamics simulations and QM/MM calculations.
Yang Y; Hu B; Yang Y; Gong K; Wang H; Guo Q; Tang X; Li Y; Wang J
Phys Chem Chem Phys; 2021 Aug; 23(32):17576-17590. PubMed ID: 34369509
[TBL] [Abstract][Full Text] [Related]
4. Design, Synthesis and Biological Evaluation of Novel N-hydroxyheptanamides Incorporating 6-hydroxy-2-methylquinazolin-4(3H)-ones as Histone Deacetylase Inhibitors and Cytotoxic Agents.
Minh NV; Thanh NT; Lien HT; Anh DTP; Cuong HD; Nam NH; Hai PT; Minh-Ngoc L; Le-Thi-Thu H; Chinh LV; Vu TK
Anticancer Agents Med Chem; 2019; 19(12):1543-1557. PubMed ID: 31267876
[TBL] [Abstract][Full Text] [Related]
5. Lansoprazole as a potent HDAC2 inhibitor for treatment of colorectal cancer: An in-silico analysis and experimental validation.
Khadempar S; Lotfi M; Haghiralsadat F; Saidijam M; Ghasemi N; Afshar S
Comput Biol Med; 2023 Nov; 166():107518. PubMed ID: 37806058
[TBL] [Abstract][Full Text] [Related]
6. Design, Synthesis and Biological Evaluation of New HDAC1 and HDAC2 Inhibitors Endowed with Ligustrazine as a Novel Cap Moiety.
Al-Sanea MM; Gotina L; Mohamed MF; Grace Thomas Parambi D; Gomaa HAM; Mathew B; Youssif BGM; Alharbi KS; Elsayed ZM; Abdelgawad MA; Eldehna WM
Drug Des Devel Ther; 2020; 14():497-508. PubMed ID: 32103894
[TBL] [Abstract][Full Text] [Related]
7. Novel N-hydroxybenzamides incorporating 2-oxoindoline with unexpected potent histone deacetylase inhibitory effects and antitumor cytotoxicity.
Huong TT; Dung DT; Huan NV; Cuong LV; Hai PT; Huong LT; Kim J; Kim YG; Han SB; Nam NH
Bioorg Chem; 2017 Apr; 71():160-169. PubMed ID: 28196602
[TBL] [Abstract][Full Text] [Related]
8. Combinatorial
Ganai SA; Abdullah E; Rashid R; Altaf M
Front Mol Neurosci; 2017; 10():357. PubMed ID: 29170627
[TBL] [Abstract][Full Text] [Related]
9. Identification of potent histone deacetylase 2 (HDAC2) inhibitors through combined structure and ligand-based designs and molecular modelling approach.
Anand A; Ghosh P; Singh R; Gajanan Bajad N; Kumar A; Singh SK
J Biomol Struct Dyn; 2024 Jun; 42(9):4679-4698. PubMed ID: 37306006
[TBL] [Abstract][Full Text] [Related]
10. Design of Potent Panobinostat Histone Deacetylase Inhibitor Derivatives: Molecular Considerations for Enhanced Isozyme Selectivity between HDAC2 and HDAC8.
Stoddard SV; May XA; Rivas F; Dodson K; Vijayan S; Adhika S; Parker K; Watkins DL
Mol Inform; 2019 Mar; 38(3):e1800080. PubMed ID: 30369061
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of class IIa histone deacetylase activity by gallic acid, sulforaphane, TMP269, and panobinostat.
Choi SY; Kee HJ; Jin L; Ryu Y; Sun S; Kim GR; Jeong MH
Biomed Pharmacother; 2018 May; 101():145-154. PubMed ID: 29482060
[TBL] [Abstract][Full Text] [Related]
12. Synthesis, Molecular Docking and Biological Characterization of Pyrazine Linked 2-Aminobenzamides as New Class I Selective Histone Deacetylase (HDAC) Inhibitors with Anti-Leukemic Activity.
Ibrahim HS; Abdelsalam M; Zeyn Y; Zessin M; Mustafa AM; Fischer MA; Zeyen P; Sun P; Bülbül EF; Vecchio A; Erdmann F; Schmidt M; Robaa D; Barinka C; Romier C; Schutkowski M; Krämer OH; Sippl W
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008795
[TBL] [Abstract][Full Text] [Related]
13. The Effects of Combinatorial Genistein and Sulforaphane in Breast Tumor Inhibition: Role in Epigenetic Regulation.
Paul B; Li Y; Tollefsbol TO
Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29899271
[TBL] [Abstract][Full Text] [Related]
14. Sulforaphane attenuates cisplatin-induced hearing loss by inhibiting histone deacetylase expression.
Wang J; Tian KY; Fang Y; Chang HM; Han YN; Chen FQ
Int J Immunopathol Pharmacol; 2021; 35():20587384211034086. PubMed ID: 34344210
[TBL] [Abstract][Full Text] [Related]
15. Discovery, bioactivity and docking simulation of Vorinostat analogues containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors and antitumor agents.
Cai J; Wei H; Hong KH; Wu X; Zong X; Cao M; Wang P; Li L; Sun C; Chen B; Zhou G; Chen J; Ji M
Bioorg Med Chem; 2015 Jul; 23(13):3457-71. PubMed ID: 25953722
[TBL] [Abstract][Full Text] [Related]
16. Sulforaphane-N-Acetyl-Cysteine Induces Autophagy Through Activation of ERK1/2 in U87MG and U373MG Cells.
Liu HJ; Wang L; Kang L; Du J; Li S; Cui HX
Cell Physiol Biochem; 2018; 51(2):528-542. PubMed ID: 30458452
[TBL] [Abstract][Full Text] [Related]
17. Influence of side-chain changes on histone deacetylase inhibitory and cytotoxicity activities of curcuminoid derivatives.
Somsakeesit LO; Senawong T; Kumboonma P; Saenglee S; Samankul A; Senawong G; Yenjai C; Phaosiri C
Bioorg Med Chem Lett; 2020 Jun; 30(11):127171. PubMed ID: 32273215
[TBL] [Abstract][Full Text] [Related]
18. Novel 3-substituted-2-oxoindoline-based N-hydroxypropenamides as histone deacetylase inhibitors and antitumor agents.
Dung do TM; Dung PT; Oanh DT; Hai PT; Huong le TT; Loi VD; Hahn H; Han BW; Kim J; Han SB; Nam NH
Med Chem; 2015; 11(8):725-35. PubMed ID: 26133355
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents.
Xie R; Yao Y; Tang P; Chen G; Liu X; Yun F; Cheng C; Wu X; Yuan Q
Eur J Med Chem; 2017 Jul; 134():1-12. PubMed ID: 28391133
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and evaluation of novel indirubin-based N-hydroxybenzamides, N-hydroxypropenamides and N-hydroxyheptanamides as histone deacetylase inhibitors and antitumor agents.
Anh DT; Hai PT; Dung DTM; Dung PTP; Huong LT; Park EJ; Jun HW; Kang JS; Kwon JH; Tung TT; Han SB; Nam NH
Bioorg Med Chem Lett; 2020 Nov; 30(22):127537. PubMed ID: 32916298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
